Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
USRM (OTCMarkets) -Stamcellen-
Volgen
Straks geen schulden meer en zwarte cijfers. Ik denk dat het de beste koop momenteel is op dit Niveau voor een OTC bedrijf.
Lijkt wat activiteit in te zitten. De kwartaal en jaarcijfers zijn steeds beter. 5 mil. handel tot nu toe en staat weer op 5 cent. Weinig Nederlandse belangstelling? Stamcel verhaal van dit bedrijf is toch wel erg interessant voor ieder mens. Grote veranderingen in de gezondheidszorg met deze methodiek.
Momenteel 0,057 cent, volgende week de jaarcijfers. Zo te zien zijn de verwachtingen al daar.
7 cent onder enig nieuws nog. De jaarcijfers , dan kwartaalcijfers en verder nog RMAT in de toekomst. Mocht dat goedkeuring krijgen (Myocell) dan praat je over mogelijk miljarden tzt. Dat zal onherroepelijk reflecteren in een veel hogere prijs per aandeel. De ontwikkeling van Myocell heeft 100 mil. gekost over 2 decades. Bovenal, komen in de plus regionen, dus winst,(op andere onderdelen) OTC zal dus in de toekomst niet meer van toepassing zijn. Nu aan 7 cent en zal een schijntje zijn in korte termijn. (dit jaar zeker) Middellange en langere termijn praten we dus over dollars per aandeel bij goedkeuring FDA. (paar jaar)
Dat ziet er toch niet zo goed uit voor de aandelen?www.kijkmagazine.nl/mens/man-injectee...
Ziet er zeker goed uit. Heb de reportage van 'kijk' gelezen en het is duidelijk met ongefundeerde onderbuikgevoelens geschreven. Immers, de drie patiënten die blind werden deden mee met dit onderzoek wetende dat het kon mislukken. Ze hebben overigens wel een schadevergoeding ontvangen. Het belang van deze frontrunners moet niet onderkend worden. Ik zou het zelf niet doen maar als andere mensen als uiterste redmiddel wel hierin meegaan kan ik zeer goed begrijpen. We willen immers allemaal blijven leven en kwalitatief welzijn. Nu heeft iemand voor een longziekte ook deze procedure ondergaan omdat er niets te verliezen valt. Bij deze zijn engelse tekst:My name is Dan, and I live in North Dakota. Long story short, I have a severe lung disease. I've wanted to do a stem cell treatment for a long time, and figured I couldn't wait any longer. I am in and out of the hospital a lot, and was last in the hospital in December with Influenza A. I didn't think I was going to make it out, but I did. The doctors are giving me about a year to live, so I knew I had to do something fast. I knew I couldn't fly anymore, and had to find something closer where I could drive to, so I found out a place in Kansas City call "KansasRMC" and I could do it there. I texted Dr. Comella and she said they are a legit clinic. So, I went there and did a treatment (adipose) there last Thursday, March 8. They put my stem cells back in via IV and nebulizer. Today is my 53rd birthday, and I hope to live to see another one! I have 150,000 reason that USRM will do well, and the fact that I believe in them. I will keep you updated about each month as to how I'm doing. It's suppose to take up to 3 months to see some improvement. I'm praying that it will. God Bless you all! Ik hoop ten zeerste dat hij hier goede resultaten mee haalt. Ik ben natuurlijk investeerder in dit bedrijf en zie bijzonder veel mogelijkheden voor deze technieken in de toekomst, dus stijgend aandeel. Wat belangrijker is; dat we als samenleving mogen profiteren van de mogelijkheden op dit gebied. Als je kijkt naar de resultaten voor kniebehandelingen met veel succes dan belooft dit veel goeds voor de toekomst. Het zijn je eigen cellen dus geen medicatie. Als er ièts s waar ik geen voorstander van ben dan zijn het wel medicijnen. Tuurlijk helpen ze legio mensen maar het vervelende is dat het niets oplost maar puur symptoombestrijding is. Stam cel behandelingen kunnen wel degelijk iets maken door eigen herstel te ondersteunen met eveneens eigen stamcellen. We gaan hier echt veel meer van horen in de toekomst.
Reminder, morgen jaarcijfers.
Bijzonder goed nieuws!!! USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem CellsAutoimmune Skin Condition Affects More Than 7 million in the United States PR NEWSWIRE 10:29 AM ET 3/21/2018 Symbol Last Price Change USRM 0.0655down +0.0055 (+9.17%) QUOTES AS OF 10:33:14 AM ET 03/21/2018 SUNRISE, Fla. , March 21, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient's autologous stem cells. (PRNewsfoto/U.S. Stem Cell, Inc.) The scientific paper, which is authored by USRM Chief Science Officer Dr. Kristin Comella and her USRM colleagues, is published in the International Medical Case Reports Journal, 2018:11 59-64. To the best of USRM management's knowledge, this is the first result in the world published using stromal vascular fraction (SVF) and autologous stem cells in the successful treatment of psoriasis. "This is a breakthrough for the more than 7 million Americans suffering from psoriasis, and is another example of how a patient's own stem cells offer healing modalities for autoimmune conditions," said Dr. Comella. "Although we require additional studies to further develop more extensive protocol in treating patients with this condition, this is a benchmark indicating there is significant reason to believe the use of autologous stem cells is beneficial in combating this disease." Stromal vascular fraction (SVF) is a mixture of adipose-derived stem cells/mesenchymal stem cells, endothelial/progenitors, pericytes, fibroblasts, and other cells) obtained from a patient's own fat tissue. Approximately 60 mL was collected under local anesthesia via a mini-lipoaspirate procedure, which was then separated from the adipocytes via centrifugation after utilizing USRM's AdipocellTM kit to apply enzymatic digestion. The cells were then resuspended in normal saline and injected via intravenous bolus push. The subject was monitored over a period of 12 months, and demonstrated no safety or adverse events. The subject demonstrated a significant (99%) decrease in symptoms with a noticeable difference in skin quality appearance. Psoriasis area and severity index score went from 50.4 at baseline to 0.3 at 1 month follow-up. Overall, the subject reported improved quality of life and willingness to continue treatments. This successful initial case study demonstrates that this may be a feasible treatment plan for patients suffering from psoriasis. In this scientific paper, Dr. Comella et al. describe the rationale and, to their knowledge, the first clinical implementation of SVF intravenously in a patient with severe psoriasis. "We are so proud of the work Dr. Comella and our team are doing to forge novel applications of autologous stem cells to treat a whole host of autoimmune issues," said Mike Tomas, USRM's Chief Executive Officer. "What better fit for a patient than their own stem cells as a healing treatment. We look forward to continued investigation of this and other conditions to treat with autologous stem cells." Psoriasis is an autoimmune disease affecting 2 percent of the population worldwide and approximately 7.5 million people in the United States1. Psoriasis patients present with erythematous scaly well-defined plaques, with the scalp, knees, elbows, hands, and feet being the most commonly affected areas.2 Approximately 20% of psoriasis patients present with moderate to severe psoriasis, with more than 5% of the body surface affected. Fifteen percent of patients with psoriasis will develop psoriatic arthritis, occasionally with joint complaints such as dactylitis, sacroiliitis, enthesopathy, and spondylitis, occurring before cutaneous psoriasis. This condition can cause joint destruction due to the chronic inflammation. There are also significant comorbidities associated with psoriasis, including a 58% risk of cardiovascular disease and 43% increased risk of stroke. The risk of diabetes is 30% higher in patients with severe psoriasis. Multipotential/Mesenchymal adult stem cells (MSCs) are currently being studied by USRM in a variety of diseases and injuries. MSCs can be found in many tissues throughout the body and are thought to play a critical role in a patient's healing cascade. When MSCs are placed into culture or in vitro, they demonstrate an ability to differentiate on several different tissue pathways. MSCs are part of the body's natural healing mechanism and as such represent a potential therapy in a variety of diseases, including having immunomodulatory properties and stimulating a healing response by reducing inflammation. For this reason, MSCs may be beneficial for patients experiencing excessive inflammation, as is present in autoimmune diseases like psoriasis. Dr. Comella, who has more than 20+ years' experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells. USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. U.S. Stem Cell, Inc. (USRM) is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world. 1Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. 2Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S: 2003–2006 and 2009–2010 national health and nutrition examination surveys. Am J Prevent Med. 2014;47(1):37–45.
Nog geen resultaten van 2017, goed...binnenkort.
Wat een grafiek over de laatste zes maand. De high weer opzoeken van vorige week.
Nu nog makkelijk posities te pakken. In de toekomst zal het vast niet meer op dit niveau meer kunnen. Ik kan wel zeggen; koop wanneer er een dikke uptrend is maar nu net voor een geweldige mogelijke uitbraak is toch vele malen interessanter. Do your DD
Mooi kopje aan het vormen, mooie uitbraak op de loer, fundamenteel en technisch geweldig plaatje.
Heee Elio, ik zie dat jij veelal in de OTC. Daar heb ik ook wel eea aan aandelen in gekocht. Waarom is dit aandeel van 0,08 weer terug naar 0,03 gegaan? Is daar een verklaring voor? Hoe kijk jij nu tegen dit aandeel aan?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
866,51
0,00%
EUR/USD
1,0644
-0,07%
FTSE 100
8.023,87
0,00%
Germany40^
17.981,10
+0,67%
Gold spot
2.301,39
-1,11%
NY-Nasdaq Composite
15.451,31
+1,11%
Stijgers
Dalers